A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.
Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a study suggests. Similar studies have shown that ...
A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
News Medical on MSN3d
Living in disadvantaged areas reduces ALS survival time by over 30%Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests.
Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease ... and improving the quality of life for patients. Medications such as riluzole and edaravone have been approved to help slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback